Eligible AACR 2019 Annual Meeting Registrants – Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

Developmental Therapeutics: Clinical Results of Novel Agents

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 8 of 8
Introduction
Anthony El-Khoueiry
USC Norris Comprehensive Cancer Ctr., Los Angeles, CA, United States
from AACR Annual Meeting 2019 on April 2, 2019 3:00 PM-5:00 PM
Phase I combination study of the CHK1 inhibitor prexasertib (LY2606368) and olaparib in patients with high-grade serous ovarian cancer and other advanced solid tumors
Khanh T Do
Dana-Farber Cancer Inst., Boston, MA, United States
from AACR Annual Meeting 2019 on April 2, 2019 3:00 PM-5:00 PM
Treatment of neurofibromatosis type 1 (NF1)-related plexiform neurofibromas (PN) with cabozantinib (XL184): A Neurofibromatosis Clinical Trials Consortium Phase II trial
Amy E Armstrong
Indiana University, Riley Hospital for Children, Indianapolis, IN, United States
from AACR Annual Meeting 2019 on April 2, 2019 3:00 PM-5:00 PM
A Phase II, single arm study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic mutation in BRCA1, BRCA2 or PALB2
Kim A Reiss Binder
University of Pennsylvania, Philadelphia, PA, United States
from AACR Annual Meeting 2019 on April 2, 2019 3:00 PM-5:00 PM
A dose escalation trial of the Wee1 inhibitor AZD1775, in combination with gemcitabine and radiation for patients with locally advanced pancreatic cancer
Kyle C Cuneo
University of Michigan, Ann Arbor, MI, United States
from AACR Annual Meeting 2019 on April 2, 2019 3:00 PM-5:00 PM
Randomized, double-blind, placebo-controlled trial of preventative MUC1 vaccine in patients with newly diagnosed advanced adenomas: Results from one-year booster
Olivera J Finn
Univ. of Pittsburgh School of Medicine, Pittsburgh, PA, United States
from AACR Annual Meeting 2019 on April 2, 2019 3:00 PM-5:00 PM
Evaluation of in vivo chimeric antigen receptor (CAR) transgene levels in patients (pts) treated with tisagenlecleucel
Rakesh Awasthi
Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
from AACR Annual Meeting 2019 on April 2, 2019 3:00 PM-5:00 PM
TAS-120 in patients with advanced solid tumors bearing FGF/FGFR aberrations: A Phase I study
Funda Meric-Bernstam
University of Texas MD Anderson Cancer Center, Houston, TX, United States
from AACR Annual Meeting 2019 on April 2, 2019 3:00 PM-5:00 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 8 of 8